|
|
Article: Requip(R) (Ropinirole HCl) Tablets First and Only Medication Approved By the FDA for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome (RLS) in Adults.
- Article from:
- PR Newswire
- Article date:
- May 5, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RESEARCH TRIANGLE PARK, N.C., May 5 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has approved Requip(R) (ropinirole HCl) Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults, GlaxoSmithKline announced today. Requip is the first and only FDA-approved treatment for those patients with moderate-to-severe primary RLS, a chronic and disruptive neurological condition. RLS, which encompasses a range of severity that includes mild, moderate and severe symptoms, affects approximately one in ten adults in the U.S.
Identified in the early 1940's by neurologist Dr. Karl Ekbom, RLS is characterized by a ...